Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830932 · ClinicalTrials.gov registry record · Phase 1
Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
A Phase 1 study, sponsored by Vaxart.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02830932 is a Phase 1 study that has completed, run by Vaxart. The registered enrollment target is 66 participants.
The verdict
NCT02830932, a Phase 1 study, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Interventions
- OTHER VXA Placebo Tablets
- BIOLOGICAL VXA-RSV-f Tablets (high dose)
- BIOLOGICAL VXA-RSV-f Tablets (low dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02830932
The ClinicalTrials.gov registry entry for NCT02830932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which VXA Placebo Tablets is the first listed.
NCT02830932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02830932 about?
NCT02830932 is a clinical study titled "Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)". A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers
What is the current status of trial NCT02830932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2016-06-22. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT02830932?
The interventions under investigation include: VXA Placebo Tablets (OTHER), VXA-RSV-f Tablets (high dose) (BIOLOGICAL), VXA-RSV-f Tablets (low dose) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02830932?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.